Wulf, Gerald G.

[["dc.bibliographiccitation.firstpage","1307"],["dc.bibliographiccitation.issue","11"],["dc.bibliographiccitation.journal","Annals of Hematology"],["dc.bibliographiccitation.lastpage","1315"],["dc.bibliographiccitation.volume","90"],["dc.contributor.author","Hohloch, Karin"],["dc.contributor.author","Sahlmann, Carsten Oliver"],["dc.contributor.author","Lakhani, Vijai J."],["dc.contributor.author","Wulf, Gerald"],["dc.contributor.author","Glass, Bertram"],["dc.contributor.author","Hasenkamp, Justin"],["dc.contributor.author","Meller, Johannes"],["dc.contributor.author","Riggert, Joachim"],["dc.contributor.author","Truemper, Lorenz H."],["dc.contributor.author","Griesinger, Frank"],["dc.date.accessioned","2018-11-07T08:50:15Z"],["dc.date.available","2018-11-07T08:50:15Z"],["dc.date.issued","2011"],["dc.description.abstract","A phase II trial evaluated safety, feasibility and efficacy of a sequential tandem approach combining myeloablative BEAM chemotherapy and autologous stem cell transplantation (ASCT) with myeloablative radioimmunotherapy (HD-RIT), with I-131-anti-CD20 antibody (I-131-rituximab), followed by a second ASCT in patients with relapsed or refractory CD20+ B-cell lymphoma. According to protocol, 16 patients with relapsed (n=14) and refractory (n=2) CD20+ B-cell lymphoma received salvage therapy with rituximab and Dexa-BEAM, followed by BEAM (HD chemotherapy) and high-dose myeloablative radioimmunotherapy 2-6 months after BEAM. Nine of 16 patients received HD-RIT; seven patients were excluded before HD-RIT because of toxicity or progressive disease. Disease histologies were follicular lymphoma (FL) grades 1 and 2 (n=4), transformed follicular (FL 3b; n=6), diffuse large B-cell (DLBCL; n=4), mantle cell (n=1) and marginal zone lymphoma (n=1). After a median follow-up of 50.4 months for OS and 39.7 months for progression-free survival (PFS), estimated 4-year OS and PFS were 67% and 64%, respectively. The estimated 4-year OS and PFS for patients with FL were 80% and 78%, respectively. Toxicity was significant, including one fatal outcome due to pneumonitis. Tandem transplants consisting of HD chemotherapy followed by HD-RIT with I-131-coupled anti-CD20 are manageable and effective but toxic treatment modalities for relapsed poor prognosis CD20+ B-NHL."],["dc.identifier.doi","10.1007/s00277-011-1199-y"],["dc.identifier.isi","000296730300008"],["dc.identifier.pmid","21360108"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/7836"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/21653"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","0939-5555"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Tandem high-dose therapy in relapsed and refractory B-cell lymphoma: results of a prospective phase II trial of myeloablative chemotherapy, followed by escalated radioimmunotherapy with I-131-anti-CD20 antibody and stem cell rescue"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","341"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Annals of Hematology"],["dc.bibliographiccitation.lastpage","348"],["dc.bibliographiccitation.volume","89"],["dc.contributor.author","Hasenkamp, Justin"],["dc.contributor.author","Borgerding, Andrea"],["dc.contributor.author","Wulf, Gerald"],["dc.contributor.author","Schmitz, Norbert"],["dc.contributor.author","Truemper, Lorenz H."],["dc.contributor.author","Glass, Bertram"],["dc.date.accessioned","2018-11-07T08:44:18Z"],["dc.date.available","2018-11-07T08:44:18Z"],["dc.date.issued","2010"],["dc.description.abstract","Natural killer (NK) cells contribute to the graft-versus-leukemia effect after allogeneic stem cell transplantation. However, the efficacy of NK cell-mediated tumor cell lysis is limited due to target cell resistance, and target cell-induced apoptosis (TiA) was proposed to contribute to differences in susceptibility to NK cells. Here we analyzed the effects of target cells on the apoptosis of cytokine-activated NK cells in vitro. We found no association of target cell susceptibility and TiA of NK cells in an array of human and murine target-effector cell combinations. Incubation of NK cells with caspase inhibitors blocked TiA incompletely, indicating that TiA is partly based on caspase-independent mechanisms. Modulating NK cell susceptibility against TiA by caspase inhibition did not influence cytotoxic efficacy. Furthermore, we found cytotoxic potential of NK cells to be markedly decreased following first target cell contact. Exhaustion of NK cell activity by first target cell contact was, however, not mediated by TiA. In addition, we found no relevant TiA by lymphoma cell lines against activated murine NK cells. We conclude that TiA represents only a minor factor of target cell resistance against NK cell-mediated cytolysis."],["dc.description.sponsorship","Deutsche Krebshilfe"],["dc.identifier.doi","10.1007/s00277-009-0844-1"],["dc.identifier.isi","000274685400002"],["dc.identifier.pmid","19823823"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?goescholar/4146"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/20165"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","0939-5555"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Relevance of target cell-induced apoptosis as mechanism of resistance against natural killer cells"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","283"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Annals of Hematology"],["dc.bibliographiccitation.lastpage","289"],["dc.bibliographiccitation.volume","89"],["dc.contributor.author","Borgerding, Andrea"],["dc.contributor.author","Hasenkamp, Justin"],["dc.contributor.author","Glass, Bertram"],["dc.contributor.author","Wulf, Gerald"],["dc.contributor.author","Truemper, Lorenz H."],["dc.date.accessioned","2018-11-07T08:45:09Z"],["dc.date.available","2018-11-07T08:45:09Z"],["dc.date.issued","2010"],["dc.description.abstract","Neither effective salvage regimens nor the outcome and response to retherapy with rituximab containing chemotherapy have been defined for rituximab pre-treated patients with relapsing aggressive lymphoma. We report here a single-centre retrospective outcome analysis of second-line immunochemotherapy with rituximab. In 28 patients with relapsed or refractory diffuse large B cell lymphomas, first-line immunochemotherapy had induced objective responses in 18 patients. Nine of 28 patients responded to rituximab containing salvage therapy, leading to a median overall survival of 243 days after start of second immunochemotherapy. Long-term disease free survivors (1,260 and 949 days) were restricted to the group of twelve patients that had received allogeneic stem cell transplantation as consolidation therapy. In 21 patients with relapsed mantle cell lymphomas (MCL), 19 patients had reached remissions with first-line therapy. Of those, 16 patients experienced responses to salvage therapy with a median overall survival of 226 days. Noteworthy, none of patients with initial non-responding disease reached a remission with second immunochemotherapy. Seven patients with MCL stayed free from progression after high-dose therapy with autologous or allogeneic stem cell transplantation in two and five cases, respectively. In summary, responses to repeated immunotherapy with rituximab were observed in approximately one third and two thirds of initially responding patients with aggressive B cell lymphoma and mantle cell lymphoma, respectively, but not in primarily refractory disease. Lasting remissions were achieved only by high-dose chemotherapy with stem cell transplantation."],["dc.identifier.doi","10.1007/s00277-009-0820-9"],["dc.identifier.isi","000273785700007"],["dc.identifier.pmid","19727725"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?goescholar/4030"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/20366"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","0939-5555"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Rituximab retherapy in patients with relapsed aggressive B cell and mantle cell lymphoma"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]